PDCD1 and hepatocellular carcinoma: The combination therapy of anti-PD1/PD-L1 and anti-MDSCs (CCRK inhibition, p38 MAPK inhibitor, and C5AR blockade) may exert a synergistical effect on eradicating HCC (38, 240, 241).